Gilead Reports Strong Q2 2026 on HIV Growth but Faces Acquisition Costs — Gilead Sciences, Inc.

Event summary

Gilead reported $7.8 billion in Q2 2026 revenue, up 10% YoY, driven by HIV portfolio and Trodelvy sales.
HIV product sales grew 12%, with Biktarvy up 7% and Descovy up 48%.
$11.2 billion in acquired IPR&D expenses led to a GAAP loss of $10.5 billion for the quarter.
Gilead completed acquisitions of Tubulis ($3.15B) and Ouro Medicines ($1.675B).
FDA approved Trodelvy for first-line triple-negative breast cancer treatment.

The big picture

Gilead's Q2 results highlight its strategic focus on HIV and oncology growth, but the company faces significant financial pressures from recent acquisitions. The biopharmaceutical sector continues to prioritize M&A for pipeline expansion, while regulatory approvals remain critical for commercial success. Gilead's ability to balance integration costs with revenue growth will be key in maintaining market position.

What we're watching

Integration Challenges: How Gilead will integrate recent acquisitions and manage associated IPR&D expenses.
Regulatory Momentum: Whether the FDA approvals for Trodelvy and Hepcludex can sustain oncology growth.
HIV Market Dynamics: The pace at which PrEP business expansion will offset potential declines in other HIV products.